Rainbow Seed Fund News

  Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy data at the 2017 Association for Research in Vision and Ophthalmology (ARVO) conference showing its gene therapy QTA020V resulted in a 61% reduction in retinal ganglion cell (RGC) loss in a widely used experimental model of glaucoma. In addition, the company […]

read more

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000, and the commencement of its preclinical programmes. The round was led by The Rainbow Seed Fund who co-invested alongside Finance Wales and Dr Mark McCamish. Proceeds will be used by the company to validate […]

read more

British molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis of Alzheimer’s disease available in the US by year end. The Oxford-based firm is also in discussions with multiple pharmaceutical and biotechnology companies that wish to use its test, which is run on a custom Affymetrix microarray, to select patients […]

read more

1 2 3 18